Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1199
mi
from
Pottstown, PA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1199
mi
from
Pottstown, PA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1197
mi
from
Red Lion, PA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1197
mi
from
Red Lion, PA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1190
mi
from
Wilkes-Barre, PA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1190
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1425
mi
from
Cumberland, RI
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1425
mi
from
Cumberland, RI
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
972
mi
from
Columbia, SC
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
972
mi
from
Columbia, SC
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
882
mi
from
Greenville, SC
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
882
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
889
mi
from
Greer, SC
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
889
mi
from
Greer, SC
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
833
mi
from
Greeneville, TN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
833
mi
from
Greeneville, TN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
779
mi
from
Knoxville, TN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
779
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
618
mi
from
Nashville, TN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
618
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
664
mi
from
Tullahoma, TN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
664
mi
from
Tullahoma, TN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
688
mi
from
Corpus Christi, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
688
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
349
mi
from
Dallas, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
349
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
537
mi
from
Kerrville, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
537
mi
from
Kerrville, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
552
mi
from
Kingwood, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
552
mi
from
Kingwood, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
583
mi
from
San Antonio, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
583
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
543
mi
from
Tomball, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
543
mi
from
Tomball, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
780
mi
from
Bountiful, UT
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
780
mi
from
Bountiful, UT
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
778
mi
from
Murray, UT
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
778
mi
from
Murray, UT
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
779
mi
from
Salt Lake City, UT
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
779
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1053
mi
from
Charlottesville, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1053
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1013
mi
from
Danville, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1013
mi
from
Danville, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1118
mi
from
Falls Church, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1118
mi
from
Falls Church, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1029
mi
from
Harrisonburg, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1029
mi
from
Harrisonburg, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1020
mi
from
Lynchburg, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1020
mi
from
Lynchburg, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
979
mi
from
Roanoke, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
979
mi
from
Roanoke, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1402
mi
from
Bellevue, WA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1402
mi
from
Bellevue, WA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1407
mi
from
Tacoma, WA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1407
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
836
mi
from
Huntington, WV
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
836
mi
from
Huntington, WV
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
689
mi
from
Green Bay, WI
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
689
mi
from
Green Bay, WI
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
574
mi
from
Madison, WI
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
574
mi
from
Madison, WI
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
630
mi
from
Milwaukee, WI
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
630
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
569
mi
from
Oregon, WI
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
569
mi
from
Oregon, WI
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Belgrano,
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Belgrano,
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
571
mi
from
Saint Cloud, MN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
571
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
553
mi
from
Saint Paul, MN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
553
mi
from
Saint Paul, MN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
418
mi
from
Saint Louis, MO
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
418
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Intracoronary Imaging With NIRS-IVUS to Characterize Arterial Plaques
Multimodality Advanced Intracoronary Imaging With Near-infrared Spectroscopy and Intravascular Ultrasound to Characterize Coronary Artery Plaques Before and After Percutaneous Intervention
Status: Enrolling
Updated:  12/31/1969
Spectrum Health; Frederik Meijer Heart &Vascular Institute
737
mi
from
Grand Rapids, MI
Intracoronary Imaging With NIRS-IVUS to Characterize Arterial Plaques
Multimodality Advanced Intracoronary Imaging With Near-infrared Spectroscopy and Intravascular Ultrasound to Characterize Coronary Artery Plaques Before and After Percutaneous Intervention
Status: Enrolling
Updated: 12/31/1969
Spectrum Health; Frederik Meijer Heart &Vascular Institute
737
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated:  12/31/1969
Manhattan VA Hospital
1225
mi
from
New York, NY
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated: 12/31/1969
Manhattan VA Hospital
1225
mi
from
New York, NY
Click here to add this to my saved trials
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated:  12/31/1969
Bellevue Hospital Center
1288
mi
from
New York, NY
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated: 12/31/1969
Bellevue Hospital Center
1288
mi
from
New York, NY
Click here to add this to my saved trials
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated:  12/31/1969
New York Langone Medical Center
1286
mi
from
New York, NY
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated: 12/31/1969
New York Langone Medical Center
1286
mi
from
New York, NY
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
683
mi
from
Birmingham, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
683
mi
from
Birmingham, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
660
mi
from
Huntsville, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
660
mi
from
Huntsville, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
660
mi
from
Huntsville, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
660
mi
from
Huntsville, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
740
mi
from
Mobile, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
740
mi
from
Mobile, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
740
mi
from
Mobile, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
740
mi
from
Mobile, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
833
mi
from
Tucson, AZ
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
833
mi
from
Tucson, AZ
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
833
mi
from
Tucson, AZ
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
833
mi
from
Tucson, AZ
Click here to add this to my saved trials